FindTrial
Sign In

Profiling modifications in cell free Nucleic acid in blood plasma for cancer identification and characterization

Profiling modifications in cell free Nucleic acid in blood plasma for cancer identification and characterization(methylation + mutation ) in cell free DNA (cfDNA) for affordable diagnostic and prognostics to track recurrence for cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/109915
Enrollment
130
Registered
2026-05-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

IIIT Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with confirmed cancer and willing to participate in the study will be included in the study. Few normal individuals above 18 years would also be included in the study. Normal individuals can be young (above 18 years) as well as old, so that we can handle co-variate of age.

Exclusion criteria

Exclusion criteria: 1.below 18 years of age 2.suffering from any mental disorder. 3. Not in a condition that he/she can take decision for herself such as in coma etc

Design outcomes

Primary

MeasureTime frame
Validation of feasibility of our protocol for detection of cancer and it recurrence using cell free nucleic acid in blood plasma.Timepoint: Week 8—

Secondary

MeasureTime frame
1. Establishing liquid biopsy based diagnostic & prognostic for non-lung cancer as for lung cancer even for early detectionTimepoint: Week 8—

Countries

India

Contacts

Public ContactDr Satya Pal Kataria

Medical Oncology & haematology, Medanta The Medicity

Satya.Kataria@Medanta.org9868818541

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026